BRPI0518818A2 - sistema de distribuiÇço de proteÍna - Google Patents

sistema de distribuiÇço de proteÍna

Info

Publication number
BRPI0518818A2
BRPI0518818A2 BRPI0518818-0A BRPI0518818A BRPI0518818A2 BR PI0518818 A2 BRPI0518818 A2 BR PI0518818A2 BR PI0518818 A BRPI0518818 A BR PI0518818A BR PI0518818 A2 BRPI0518818 A2 BR PI0518818A2
Authority
BR
Brazil
Prior art keywords
vlp
protein
methods
distribution system
producing
Prior art date
Application number
BRPI0518818-0A
Other languages
English (en)
Inventor
Steen Lindkaer Jensen
Original Assignee
Bioactive Protein Delivery The
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioactive Protein Delivery The filed Critical Bioactive Protein Delivery The
Publication of BRPI0518818A2 publication Critical patent/BRPI0518818A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SISTEMA DE DISTRIBUIÇçO DE PROTEÍNA. A presente invenção está relacionada à partícula semelhante a vírus (VLP) possuindo um envelope de bicamada lipídica derivada de membrana plasmática, dita VLP compreendendo ainda uma proteína estrutural viral, ou fragmento ou derivado desse, capaz de formar uma VLP envelopada, uma proteína fusiogênica e uma proteína alvo recombinante; métodos para a distribuição das proteínas alvo recombinantes para as células usando a dita VLP, métodos terapêuticos usando a dita VLP, composições e kits compreendendo a dita VLP, métodos de produção da dita VLP, e vetores e células hospedeiras para produção da dita VLP também são descritas.
BRPI0518818-0A 2004-12-03 2005-12-05 sistema de distribuiÇço de proteÍna BRPI0518818A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0426641.7A GB0426641D0 (en) 2004-12-03 2004-12-03 Protein delivery system
PCT/GB2005/004655 WO2006059141A2 (en) 2004-12-03 2005-12-05 Protein delivery system

Publications (1)

Publication Number Publication Date
BRPI0518818A2 true BRPI0518818A2 (pt) 2008-12-09

Family

ID=36565401

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518818-0A BRPI0518818A2 (pt) 2004-12-03 2005-12-05 sistema de distribuiÇço de proteÍna

Country Status (9)

Country Link
US (1) US20090041724A1 (pt)
EP (1) EP1827394A2 (pt)
JP (1) JP2008521430A (pt)
CN (1) CN101146522A (pt)
AU (1) AU2005311033A1 (pt)
BR (1) BRPI0518818A2 (pt)
GB (1) GB0426641D0 (pt)
RU (1) RU2007125135A (pt)
WO (1) WO2006059141A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0725065D0 (en) * 2007-12-21 2008-01-30 Got A Gene Ab Method
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
WO2011058064A1 (en) 2009-11-13 2011-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Reprogrammation of eukaryotic cells with engineered microvesicles
JP5878126B2 (ja) * 2009-11-13 2016-03-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 工学操作された微小胞を用いての直接的なタンパク質の送達
WO2011120994A1 (en) * 2010-03-29 2011-10-06 Inserm (Institut National De La Sante Et De La Recherche Medicale) Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof
CN102533680B (zh) * 2011-06-24 2014-03-26 武汉生物制品研究所有限责任公司 狂犬病毒病毒样颗粒及其制备方法
US20130236456A1 (en) * 2012-03-08 2013-09-12 Georgia Health Sciences University Research Institute, Inc. IMMUNOGLOBULIN Fc FRAGMENT TAGGING ACTIVATION OF ENDOGENOUS CD4 AND CD8 T CELLS AND ENHANCEMENT OF ANTITUMOR EFFECTS OF LENTIVECTOR IMMUNIZATION
EP3663395B1 (en) 2012-03-26 2024-07-31 The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology, Transfer, Delivery of packaged rna to mammalian cells
EP2746772B1 (en) * 2012-12-20 2016-03-23 AIT Austrian Institute of Technology GmbH Lipid membrane enveloped particles with membrane proteins
WO2014210448A1 (en) 2013-06-27 2014-12-31 The Board Of Regents Of The University Of Texas System Compositions and methods relating to myomaker-induced muscle cell fusion
KR102467982B1 (ko) 2013-12-16 2022-11-16 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Vlp-레플리콘을 이용한 클래스 ii mhc 항원의 전달에 의한 암 면역요법
WO2015134365A2 (en) 2014-03-03 2015-09-11 Acharjee Sujata Chimeric dystrophin-vsv-g-protein to treat dystrophinopathies
WO2015164726A2 (en) * 2014-04-25 2015-10-29 Acharjee Sujata Chimeric vsv-g proteins as nucleic acid transfer vehicles
CN108779473A (zh) * 2016-03-16 2018-11-09 法国居里学院 用于制备具有环二核苷酸的病毒颗粒的方法和所述颗粒用于治疗癌症的用途
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
US11866699B2 (en) 2017-02-10 2024-01-09 University Of Washington Genome editing reagents and their use
ES3052812T3 (en) * 2017-05-08 2026-01-14 Flagship Pioneering Innovations V Inc Compositions for facilitating membrane fusion and uses thereof
WO2020014209A1 (en) 2018-07-09 2020-01-16 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
WO2020102485A1 (en) * 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
AU2019378036B2 (en) 2018-11-14 2026-05-07 Flagship Pioneering Innovations V, Inc Compositions and methods for compartment-specific cargo delivery
CN114258398A (zh) 2019-06-13 2022-03-29 总医院公司 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
CN114144198A (zh) * 2019-07-16 2022-03-04 科斯塔治疗公司 膜脂包覆的纳米颗粒的制备方法
JP7072604B2 (ja) * 2020-06-23 2022-05-20 アンスティテュ・クリー 環状ジヌクレオチドを含むウイルス粒子を調製する方法及びがんを治療するための前記粒子の使用
CN116670154A (zh) 2020-07-24 2023-08-29 总医院公司 增强的病毒样颗粒及使用其递送至细胞的方法
AU2022253020A1 (en) 2021-04-08 2023-10-26 Sana Biotechnology, Inc. Cd8-specific antibody constructs and compositions thereof
CN116981684A (zh) * 2021-07-22 2023-10-31 北京百普赛斯生物科技股份有限公司 一种纳米颗粒及其检测car阳性表达率的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019803A1 (en) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
WO2003027269A1 (en) * 2001-09-25 2003-04-03 Mosca Joseph D Chronic pathogen-expressing cell lines
JP2004175665A (ja) * 2002-11-22 2004-06-24 Japan Science & Technology Agency タンパク質中空ナノ粒子およびそれを用いた薬剤

Also Published As

Publication number Publication date
JP2008521430A (ja) 2008-06-26
WO2006059141A8 (en) 2007-07-05
RU2007125135A (ru) 2009-01-10
GB0426641D0 (en) 2005-01-05
WO2006059141A3 (en) 2007-08-23
AU2005311033A1 (en) 2006-06-08
US20090041724A1 (en) 2009-02-12
WO2006059141A2 (en) 2006-06-08
CN101146522A (zh) 2008-03-19
EP1827394A2 (en) 2007-09-05

Similar Documents

Publication Publication Date Title
WO2006059141A3 (en) Protein delivery system
US20230226167A1 (en) Henipavirus vaccine
BRPI0411519A (pt) membrana viral reconstituìda, método para produzir uma membrana viral reconstituìda, e, composição farmacêutica
CN120035678A (zh) 用于调节循环因子的组合物和方法
US9611481B2 (en) Chimeric polynucleotides and polypeptides enabling the secretion of a polypeptide of interest in combination with exosomes and uses thereof
CA3173922A1 (en) Rna constructs and uses thereof
JP2023549265A (ja) 脂質ナノ粒子ｍＲＮＡワクチンの安定化のための組成物および方法
CN111630173A (zh) 新型人工核酸分子
Prévôt et al. Characterization of a novel RNA‐binding region of eIF4GI critical for ribosomal scanning
WO2021198706A3 (en) Coronavirus vaccines
IL315872A (en) Preparation of therapeutic exosomes using membrane proteins
CY1121132T1 (el) ΠΛΗΡΩΣ-ΑΝΘΡΩΠΙΝΑ ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ANTI-vap-1
Makarkov et al. Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages
CN107810009A (zh) 涉及施用至少一种mRNA构建体的初免‑加强方案
BRPI0920572A8 (pt) Inativação viral durante a purificação dos anticorpos
JP2017513956A (ja) 核酸ワクチン
Katz et al. Membrane assembly: synthesis and intracellular processing of the vesicular stomatitis viral glycoprotein
BRPI0707300A8 (pt) Vacina contra vírion influenza dividido ou antígeno de superfície purificado e método para a preparação de uma composição imunogênica
Wahl et al. HLA class I molecules reflect an altered host proteome after influenza virus infection
WO2022200575A1 (en) Immunogenic compositions
US20250339506A1 (en) Compositions for use in treatment of chlamydia
Khan et al. Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein
EP4694920A1 (en) Rna for preventing or treating tuberculosis
Macioła et al. The length of N-glycans of recombinant H5N1 hemagglutinin influences the oligomerization and immunogenicity of vaccine antigen
Huang et al. DcR3 suppresses influenza virus-induced macrophage activation and attenuates pulmonary inflammation and lethality

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BIOACTIVE PROTEIN TRANSFER THERAPEUTICS LIMITED (G

Free format text: ALTERADO DE: BIOACTIVE PROTEIN DELIVERY THERAPEUTICS

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]